The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation.

Molecular and Cellular Biology
J J WestendorfS Hiebert

Abstract

AML-1B is a hematopoietic transcription factor that is functionally inactivated by multiple chromosomal translocations in human acute myeloblastic and B-cell lymphocytic leukemias. The t(8;21)(q22;q22) translocation replaces the C terminus, including the transactivation domain of AML-1B, with ETO, a nuclear protein of unknown function. We previously showed that AML-1-ETO is a dominant inhibitor of AML-1B-dependent transcriptional activation. Here we demonstrate that AML-1-ETO also inhibits C/EBP-alpha-dependent activation of the myeloid cell-specific, rat defensin NP-3 promoter. AML-1B bound the core enhancer motifs present in the NP-3 promoter and activated transcription approximately sixfold. Similarly, C/EBP-alpha bound NP-3 promoter sequences and activated transcription approximately sixfold. Coexpression of C/EBP-alpha with AML-1B or its family members, AML-2 and murine AML-3, synergistically activated the NP-3 promoter up to 60-fold. The t(8;21) product, AML-1-ETO, repressed AML-1B-dependent activation of NP-3 and completely inhibited C/EBP-alpha-dependent activity as well as the synergistic activation. In contrast, the inv(16) product, which indirectly targets AML family members by fusing their heterodimeric DNA binding ...Continue Reading

References

Dec 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·H MiyoshiM Ohki
Jan 25, 1991·Cell·R I LehrerM E Selsted
Jan 25, 1991·Cell·C L SawyersO N Witte
Aug 1, 1991·Molecular and Cellular Biology·G P OwensJ J Cohen
Jan 1, 1990·European Journal of Haematology·T GanzR I Lehrer
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·K A DaherM Kronenberg
Sep 1, 1982·Molecular and Cellular Biology·C M GormanB H Howard
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·T R GolubD G Gilliland
Apr 1, 1995·Molecular and Cellular Biology·S MeyersS W Hiebert
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·G NuciforaJ D Rowley
Jul 12, 1993·FEBS Letters·R LinzmeierT Ganz
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·E OgawaY Ito
Jan 1, 1993·Annual Review of Immunology·R I LehrerT Ganz
Dec 1, 1995·Molecular and Cellular Biology·S W HiebertJ L Cleveland
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·Q WangN A Speck
Apr 1, 1996·Molecular and Cellular Biology·S W HiebertS Meyers
Sep 1, 1996·Molecular and Cellular Biology·M OelgeschlägerA D Friedman
Jan 1, 1995·Critical Reviews in Eukaryotic Gene Expression·S Meyers, S W Hiebert
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·L KlampferS D Nimer
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·D E ZhangD G Tenen
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·S FearsG Nucifora

❮ Previous
Next ❯

Citations

Dec 21, 2000·Current Oncology Reports·A JakubowiakS D Nimer
Nov 25, 2000·British Journal of Haematology·C AdidaH Dombret
Jan 29, 2003·The Journal of Biological Chemistry·Rachel A Kahler, Jennifer J Westendorf
Feb 4, 2003·Nature Reviews. Cancer·Daniel G Tenen
Oct 13, 2004·Proceedings of the National Academy of Sciences of the United States of America·Timothy S FenskeTimothy A Graubert
May 25, 2005·Stem Cells and Development·Gurudutta U GangenahalliT Ravindranath
Apr 7, 2006·Journal of Cellular Biochemistry·Amaya Puig-Kröger, Angel Corbí
Feb 1, 2006·The Journal of Experimental Medicine·Hanna S RadomskaDaniel G Tenen
Apr 23, 2009·Journal of Cellular and Molecular Medicine·Pallavi GuptaRajendra P Tripathi
Aug 13, 2013·Journal of the Egyptian National Cancer Institute·Neemat KassemHamdy M Zawam
Feb 14, 2015·Expert Opinion on Drug Safety·Myrna Candelaria, Alfonso Dueñas-Gonzalez
Mar 30, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Maria AdamakiMaria Moschovi
Jan 1, 1998·Journal of Cellular Biochemistry·Randy Fenrick, Scott W Hiebert
Mar 8, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·Y Tsutsumi-IshiiI Nagaoka
Jan 5, 2002·Proceedings of the National Academy of Sciences of the United States of America·Songyun ZhuRobert C Smart
Mar 29, 2002·Genes, Chromosomes & Cancer·Stephen E LangabeerDavid C Linch
Nov 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Karina BarseguianGary S Stein
Mar 20, 2003·Cancer Investigation·Joäelle MichaudRobert Escher
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Danilo PerrottiMichael A Caligiuri

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.